Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study.
We report the effect of continuous treatment with alendronate for 6 yr vs. placebo in the Early Postmenopausal Intervention Cohort study. A total of 1609 healthy, early postmenopausal women were recruited; we describe results for the 585 women who received continuous placebo or alendronate (2.5 or 5 mg) daily for 6 yr. Bone mineral density (BMD) was evaluated at the lumbar spine, hip, forearm, and total body at baseline and annually thereafter. Bone turnover markers were measured every 6 months from baseline to yr 2 and annually thereafter. Adverse experiences, including upper gastrointestinal events and fractures, were recorded throughout the study. Women receiving placebo experienced progressive decreases in BMD at all skeletal sites. Patients receiving alendronate experienced significant gains in spine and hip BMD that were maintained through yr 6. Significantly greater, dose-related decreases in bone turnover markers in the alendronate groups vs. placebo occurred within the first year and were sustained through yr 6. Women receiving alendronate had adverse experience incidences similar to those receiving placebo. Fractures occurred in 11.5, 10.3, and 8.9% of women taking placebo, 2.5 mg alendronate, or 5 mg alendronate daily, respectively. Therapy with alendronate is an effective and promising strategy for the prevention of postmenopausal osteoporosis.
Oregon Osteoporosis Center, 5050 Northeast Hoyt, Suite 651, Portland, Oregon 97213, USA. mmcclung@orost.com
Michael R
MR
McClung
Richard D
RD
Wasnich
David J
DJ
Hosking
Claus
C
Christiansen
Pernille
P
Ravn
Mei
M
Wu
Ann Marie
AM
Mantz
John
J
Yates
Philip D
PD
Ross
Arthur C
AC
Santora
D019386:Alendronate / Q000008:administration & dosage* / Q000009:adverse effects; D015415:Biomarkers; D015519:Bone Density / Q000187:drug effects; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000517:prevention & control*; D017698:Postmenopause; D016896:Treatment Outcome
D015415:Biomarkers; D019386:Alendronate